


Health Technology Assessment Policy and Methods Review

Consultation plan



Our stakeholders represent a diverse range of individuals and groups with a broad range of experiences and knowledge. The consultation activities have been planned to ensure that all stakeholders are able to meaningfully and constructively contribute to the Review so that the Reference Committee has a well-informed understanding of issues and perspectives to inform its recommendations to Government.

Planned consultation for the Review includes several opportunities for stakeholders to get involved at different phases through a variety of methods to ensure accessibility for the diverse needs and preferences of stakeholders. For further details on how to get involved or to make accessibility arrangements to be able to participate, please email HTAReviewConsult@health.gov.au

	Timing	Goals	Key stakeholders	Method/s	Notification
Consultation 1 (C1)	Open for 8 weeks From 11 April 2023	This phase seeks broad engagement to provide early guidance into the Review focused on the key objectives.	Open for all stakeholders to participate, including (but not limited to): <ul style="list-style-type: none"> • Patients, carers and consumers • Clinicians and clinical groups • Industry • HTA Evaluators, research, and academic groups • State and Territory Governments • Federal Government Departments • Not for Profit and Non-Government Organisations 	The process will seek responses to questions designed to guide submissions in line with the objectives as defined in the ToR through: <ul style="list-style-type: none"> • Written online submission • Online forums 	Consultation hub, Health website, Pharmaceutical Benefits Scheme (PBS) news item, and email notifications to known key stakeholders.
Consultation deep dives (CDD)	Throughout the Review	This phase seeks to gain an in-depth understanding for specific complex topics, issues, challenges, and opportunities for HTA.	It will target stakeholders with in-depth knowledge or understanding on a topic or issue highly relevant to the review, including (but not limited to): <ul style="list-style-type: none"> • Patients and consumers • HTA Experts • Parallel policy reform areas • International counterparts • Researchers, clinical and academic groups • Industry 	This process will involve a combination of in-person discussions, Webex and written submissions as agreed by the Reference Committee.	An EOI will be open on consultation hub. Topics and stakeholders agreed by the Reference Committee will be contacted directly.
Consultation 2 (C2)	Open from 22 January 2024 to 23 February 2024	This phase will workshop options with stakeholders to understand potential implications and identify unintended outcomes.	Open for all stakeholders to participate, including (but not limited to): <ul style="list-style-type: none"> • Patients, carers and consumers • Clinicians and clinical groups • Industry • HTA Evaluators, research, and academic groups • State and Territory Governments • Federal Government Departments • Not for Profit and Non-Government Organisations 	This process will seek responses to an Options Paper, developed by the Reference Committee, through: <ul style="list-style-type: none"> • Written online submission • Online workshops* / group forums* • In person workshops* / group forums* 	Consultation hub, Health website, Pharmaceutical Benefits Scheme (PBS) news item, and email notifications to known key stakeholders.

